meta|Evidence - COVID-19
click on circles to display study description...
baricitinib (n=4148) vs. standard of care (n=4008)
randomized controlled trial some concerns about risk of bias
baricitinib 4 mg once daily
baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner
usual standard of care alone
COVID 19 all comers
open-label
tocilizumab (n=161) vs. placebo (n=81)
randomized controlled trial low risk of bias
Tocilizumab
Tocilizumab single dose (8 mg per kilogram of body weight administered intravenously, not to exceed 800 mg) plus standard of care.
Placebo
COVID 19 all comers
Age > 18 and < 80 years old, Male or female gender, Confirmed SARS-CoV-2 infection by NP swab PCR, Admitted to non-ICU level care at MGH WITH evidence of severe COVID-19 (at least 2 of the following): Fever > 38C, Pulmonary infiltrates on chest X ray, Need for supplemental O2 to maintain saturation > 92% AND at least 1 of the following: Ferritin > 500 ng/ml, CRP > 50 mg/L, LDH >250 U/L, D-dimer > 1000 ng/mL.
Double-blind.
7 Boston hospitals, United States.
tocilizumab (n=136) vs. standard of care (n=134)
randomized controlled trial risk of bias NA
experimental: intervention early administration of tocilizumab associated with hydroxychloroquine and azithromycin
tocilizumab 162 mg sc x 2 doses tocilizumab 162mg sc x 2 doses at 12 hours (day 1)hydroxychloroquine 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)azithromycin 500 mg / day v.o. for 3 days
hydroxychloroquine and azithromycin
hydroxychloroquine 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)azithromycin 500 mg / day v.o. for 3 days
COVID 19 all comers
open-label
Spain
pilot, randomized, multicenter, open-label clinical trial
powered by vis.js Network